AI English summary of an SEC filing — figures as filed
AbbVie ABBVAbbVie said its GAAP and adjusted non-GAAP earnings for Q3 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis. The company said this expense represents an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
Key points
AI summaryAbbVie said its GAAP and adjusted non-GAAP earnings for Q3 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis. The company said this expense represents an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
AbbVie said its adjusted diluted earnings per share guidance range for Q3, including the impact of Q3 acquired IPR&D and milestones expense, is $3.73 - $3.77. The company said the previously announced guidance range excluding this expense was $3.84 - $3.88 (in millions, except per share data).
AbbVie said its full-year 2026 adjusted diluted earnings per share guidance range, including the impact of Q3 acquired IPR&D and milestones expense, is $13.76 - $13.96. The company said the previously announced guidance range on July 31 was $13.87 - $14.07 (in millions, except per share data).
AbbVie presented in the table its full-year 2026 acquired IPR&D and milestones expense as $1,251 million, which is the previously announced guidance of $1,035 million plus Q3 acquired IPR&D and milestones expense of $216 million (in millions). The company said acquired IPR&D and milestones expense that may be incurred beyond Q3 cannot be reliably forecasted and is excluded from guidance.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 2026 Acquired IPR&D and Milestones Expense $216 million
AbbVie said its GAAP and adjusted non-GAAP earnings for Q3 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis. The company said this expense represents an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
Source · Based on the filing body and exhibits
Q3 Adjusted Diluted Earnings Per Share Guidance $3.73 - $3.77
AbbVie said its adjusted diluted earnings per share guidance range for Q3, including the impact of Q3 acquired IPR&D and milestones expense, is $3.73 - $3.77. The company said the previously announced guidance range excluding this expense was $3.84 - $3.88 (in millions, except per share data).
Source · Based on the filing body and exhibits
Full-Year Adjusted Diluted Earnings Per Share Guidance $13.76 - $13.96
AbbVie said its full-year 2026 adjusted diluted earnings per share guidance range, including the impact of Q3 acquired IPR&D and milestones expense, is $13.76 - $13.96. The company said the previously announced guidance range on July 31 was $13.87 - $14.07 (in millions, except per share data).
Source · Based on the filing body and exhibits
Full-Year Acquired IPR&D and Milestones Expense Guidance $1,251 million
AbbVie presented in the table its full-year 2026 acquired IPR&D and milestones expense as $1,251 million, which is the previously announced guidance of $1,035 million plus Q3 acquired IPR&D and milestones expense of $216 million (in millions). The company said acquired IPR&D and milestones expense that may be incurred beyond Q3 cannot be reliably forecasted and is excluded from guidance.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…